Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
Immunomedics reports CD22 antibody produced significant anti-tumor response

Immunomedics reports CD22 antibody produced significant anti-tumor response

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

Merrimack receives $2.44 million under QTDP program to support cancer research

Merrimack receives $2.44 million under QTDP program to support cancer research

Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

Amgen to present oncology portfolio results at ESMO Congress

Amgen to present oncology portfolio results at ESMO Congress

Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research

Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research

Merck Serono to present Erbitux data at ESMO Congress

Merck Serono to present Erbitux data at ESMO Congress

Amgen announces PRIME '203' and '181' Phase 3 trial results

Amgen announces PRIME '203' and '181' Phase 3 trial results

Arno Therapeutics closes private placement to advance cancer treatment

Arno Therapeutics closes private placement to advance cancer treatment

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

In vitro HDRA improves survival, prognosis of patients with NSCLC: Study

In vitro HDRA improves survival, prognosis of patients with NSCLC: Study

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

NICE draft guidance rejects cancer drug bevacizumab

NICE draft guidance rejects cancer drug bevacizumab

SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy

SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy